<DOC>
	<DOCNO>NCT00100009</DOCNO>
	<brief_summary>This study test safety effectiveness combine laser treatment call photodynamic therapy , PDT , injection eye steroid triamcinolone acetonide treat age-related macular degeneration ( AMD ) . The macula part retina back eye determine central best vision . AMD severely impair central vision , affect person 's ability read , drive , carry daily activity . This vision loss cause formation abnormal blood vessel behind retina leak blood macula . PTD stop growth blood vessel slow rate vision loss ; however , temporary effect work patient . Furthermore , may actually cause swell re-growth blood vessel . Triamcinolone acetonide help lessen swell scar . Patients 50 year age old AMD may eligible study . Candidates screen medical history , medical evaluation , eye examination ( see ) . Participants randomly assign one three treatment group : 1 ) PDT plus 1 mg TAC-PF ; 2 ) PDT plus 4 mg TAC-PF ; 3 ) PDT plus sham injection ( syringe needle press eye ) . Treatments give day patient enrolls study every 3 month 2 year , long therapy think beneficial . Patients must discontinue TAC-PF injection may still treat PDT medically necessary . In addition treatment , patient undergo follow test procedure : - Eye examination : Visual acuity eye pressure measure , lens , retina , pupils eye movement examine . - Fundus photography : Photographs back eye take use special camera bright flash . - Lens photography : Photographs lens take look development cataract . - Fluorescein angiography : Pictures retina take look abnormal blood vessel . A yellow dye inject arm vein travel blood vessel eye . The retina photograph use camera flash blue light eye . The picture show dye leak vessel retina , indicate possible blood vessel abnormality . - Optical coherence tomography : This test use light produce 2-dimensional cross-sectional picture retina . The patient look machine call optical coherence tomograph pattern flash rotate red green light , first one eye . - PDT : A needle place arm vein drug call verteporfin ( VisudyneÂ® ( Registered Trademark ) ) infuse vein 10 minute . After 15 minute , eye anesthetize numbing drop . A special contact lens place eye laser beam direct eye 83 second . - TAC-PF injection ( TAC-PF treatment group ) : Numbing anesthetic drop place surface eye injection TAC-PF . Another anesthetic apply low part eye cotton swab . After minute , TAC-PF inject vitreous ( jelly-like substance inside eye ) . Patients receive sham injection undergo identical procedure , except syringe needle press eye seem like real injection . All patient receive antibiotic drop put eye 2 day treatment . Patients return clinic anytime 2 7 day treatment check vision , eye pressure , treatment side effect . Patients see clinic additional check 4 week 4 month first treatment .</brief_summary>
	<brief_title>Triamcinolone Acetonide Plus Laser Therapy Treat Age-Related Macular Degeneration</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) represent common cause blindness person age 50 . The major cause vision loss disease due development choroidal neovascularization . Several clinical trial show eye neovascularization portend 4 disc area le lesion predominately classic composition ( lesion least 50 % vessel readily demarcate fluorescein angiography ) benefit treatment photodynamic therapy ( verteporfin - PDT ) . However , treatment result reduction number participant suffer moderate severe vision loss . Few participant demonstrate improvement visual acuity . Histopathologic study demonstrate presence inflammatory response retina choroid participant choroidal neovascularization well eyes receive verteporfin - PDT . Therefore , use triamcinolone acetonide , possess anti-inflammatory well anti-angiogenic property , may beneficial participant neovascular AMD undergo verteporfin - PDT . This study organize control , participant mask , randomize , multi-center Phase II/III study investigate efficacy preservative - free intravitreal formulation triamcinolone acetonide ( TAC-PF ) AMD participant undergo verteporfin - PDT . Unlike study use steroid contain benzyl alcohol , study evaluate preservative-free steroid . Three hundred participant neovascular AMD , undergo verteporfin - PDT , randomly assign receive either sham intravitreal injection , 1 mg intravitreal injection TAC-PF , 4 mg intravitreal injection TAC-PF . Depending participant 's response , treatment randomize , may repeat 3-month interval . Participants complete maximum 2 year follow-up . The primary efficacy outcome measure proportion participant experience moderate vision loss define drop great equal 15 letter best-corrected visual acuity baseline verteporfin - PDT treatment month 12 . Secondary outcome include assessment safety adjunct therapy ; additional vision change observe baseline , month 3 , month 12 , month 24 ; lesion change observe baseline , month 3 , month 12 month 24 ; change observe lens opacity baseline , month 12 , month 24 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible study , participant must fulfill follow criterion : 1 . Understand sign IRBapproved inform consent document study . 2 . Age great equal 50 year . 3 . In study eye , diagnosis AMD define presence drusen large 63 micro m. 4 . In study eye , participant le three prior pegaptanib sodium ( Macugen ( Trademark ) ) injection , without injectionrelated complication , ( endophthalmitis , vitreal hemorrhage , elevation IOP great equal 10 mmHg compare baseline ) , participant 's study eye vision 20/40 20/125 , last pegaptanib sodium injection occur great 6 week prior randomization . 5 . In study eye , presence choroidal neovascularization fovea determine site Investigator define one follow fluorescein angiographic ( FA ) feature : 1 . Early stipple hyperfluorescence flat retinal pigment epithelium little mild leakage late frame fluorescein ( occult ) . 2 . Irregular elevation retinal pigment epithelium exhibit discrete bright hyperfluorescence early transit phase angiogram . Stippled hyperfluorescence may present . Late frame may show persistent fluorescein stain leakage within sensory retinal detachment overlie area ( occult ) . 3 . Latephase leakage undetermined source leakage level retinal pigment epithelium latephase frame angiogram source late leakage determine earlierphase frame angiogram ( occult ) . 4 . A welldemarcated area bright hyperfluorescence early phase angiogram leakage mid latephase frame obscure boundary area ( classic ) . 6 . For CNV lesion consider occult CNV classic CNV , one follow criterion must meet : 1 . A documented loss visual acuity ( 5 letter bestcorrected visual acuity measurement make use ETDRS chart , double visual angle Snellen acuities available either outside referral center within participate center ( e.g. , 20/80 20/160 double visual angle require measurement variability Snellen acuity ) ) . OR 2 . Documented fluorescein angiographic evidence great equal 10 % increase lesion great linear dimension 3 month prior enrollment . OR 3 . Documented blood associate CNV . 7 . The great linear dimension entire lesion ( classic CNV , occult CNV feature could obscure identification classic occult CNV ) less equal 5400 micro great linear dimension retina measure treating ophthalmologist . 8 . Visual acuity 20/40 20/200 ( 7334 letter score ) measure ETDRS chart . 9 . Retinal photograph angiography sufficient quality , allow assessment macular area accord standard clinical practice , obtain . 10 . Women childbearing potential must pregnant lactating , must negative pregnancy test screening must practice adequate method birth control . Acceptable method birth control include intrauterine device ( IUD ) ; oral , dermal ( patch ) , implant injected contraceptive ; tubal ligation ; barrier method spermicide . 11 . Willingness comply protocol . EXCLUSION CRITERIA : Participants meet follow criterion exclude study : 1 . Choroidal neovascularization , study eye , associate ocular disease pathologic myopia , ocular histoplasmosis posterior uveitis , etc . 2 . Presence geographic atrophy fovea study eye . 3 . Evidence retinal angiomatous proliferation suspect presence intraretinal hemorrhage , intraretinal leakage , adjoin serous PED presence connect retinal vessel . 4 . The presence chorioretinal anastomosis . 5 . Decreased vision , study eye , due retinal disease attributable CNV , nonexudative form AMD , geographic atrophy , inherit retinal dystrophy , uveitis epiretinal membrane . Participants additional ocular disease irreversibly compromise , followup , could likely compromise VA study eye include amblyopia , anterior ischemic optic neuropathy , clinically significant diabetic macular edema , severe nonproliferative diabetic retinopathy , proliferative diabetic retinopathy . 6 . Decreased vision , study eye , due significant medium opacity corneal disease cataract , opacity preclude photography retina ; tear ( rip ) RPE ; vitelliformlike lesion outer retina ( e.g. , pattern dystrophy basal laminar drusen ) , idiopathic parafoveal telangiectasis , central serous retinopathy . 7 . Presence fibrosis , hemorrhage , pigment epithelial detachment hypofluorescent lesion obscure great 50 % CNV lesion . 8 . History antiangiogenic treatment treatment CNV ( include photodynamic therapy pegaptanib sodium injection ) study eye transpupillary thermotherapy local treatment ( submacular surgery ) . Previous laser photocoagulation therapy acceptable , provided subfoveal . 9 . History photodynamic therapy ( PDT ) within 1 year enrollment . 10 . Current exam evidence ocular toxoplasmosis ; pseudoexfoliation ; external ocular infection , include conjunctivitis ; chalazion ; significant blepharitis ; aphakia study eye ( pseudophakic participant eligible ) . 11 . History ocular hypertension intraocular pressure ( IOP ) great equal 25 mm Hg , participant Cosopt one topical glaucoma medication great 2 topical glaucoma medication , include Cosopt ; recent visual field , perform within last 12 month , abnormal attributable participant 's macular disease ; optic disc appear glaucomatous . 12 . Intraocular surgery ( include lens replacement surgery ) within 6 week prior randomization . 13 . Recent history ( within last 6 month ) , current acute ocular periocular infection ( include history ocular herpes zoster simplex ) . 14 . History prior treatment intravitreal corticosteroid . 15 . History peribulbar steroid injection within 6 month prior randomization . 16 . History oral steroid use time 30 day prior randomization . 17 . History untoward complication corticosteroid therapy , include elevate intraocular pressure response topical periocular corticosteroid require IOPlowering treatment . 18 . Known hypersensitivity/allergy verteporfin , porfimer sodium , porphyrin , porphyria porphyrin sensitivity , hypersensitivity sunlight bright artificial light . 19 . Participation clinical study receiving , receive experimental systemic treatment AMD ( e.g . : retinoic acid , thalidomide ) investigational new drug within 12 week prior start study treatment . 20 . Medical problem make consistent followup treatment period unlikely ( e.g . stroke , severe MI , end stage malignancy ) , contraindication perform necessary diagnostic study ( i.e. , know allergy fluorescein dye , etc . ) , general poor medical risk systemic disease active uncontrolled infection . 21 . History moderate severe abnormal liver function , unless document evidence normal liver enzymes provide .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 20, 2006</verification_date>
	<keyword>Steroid</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Intravitreal Injection</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
</DOC>